OR WAIT null SECS
JSS acquires Max Neeman International, India’s leading contract research organization with 6 regional offices
MONTREAL, CANADA, May 4th, 2015â JSS Medical Research Inc., a Montreal based Contract Research Organization (CRO), announced today that it concluded the acquisition of Max Neeman International (MNI), with head office in New Delhi, India. Additional regional offices are located in Ahmedabad, Bangalore, Chennai and Mumbai. Through a US subsidiary, a regional office is located North Carolina, USA.
This international expansion is supported by the recent equity investment transaction into JSS with Capital Croissance PME (CCPME), a joint fund by Caisse de dépôt et placement du Québec (“CDPQ”) and by Capital régional et coopératif Desjardins (“CRCD”).
This global expansion in India follows the acquisition of Latam Clinical Trials, a CRO in Bogota, Colombia that established the company’s presence in Latin America. In 2014 the merger with Integrated Research, a Montreal based CRO consolidated its position as the largest Canadian owned CRO.
“Our collaborations with MNI in recent years have enabled us to have firstâhand evidence of the quality, integrity, credibility and client centric focus of this organization that is comparable to our philosophy. Under our aegis our clients will be reassured that the work that will be conducted by our colleagues will continue to be of the highest uncompromised standards that have been the basis of the success of JSS Medical Research since its foundation over 20 years ago” mentioned Stella Boukas, COO of JSS Medical Research.
“The Max India group has nurtured Max Neeman to become a world class CRO with strong values and deep customer relationships. As a natural owner of this business, JSS Medical Research will provide a larger network of clients and invest in Max Neeman's growth, enabling the Max India group to focus on its core businesses”, said Rahul Khosla, Managing Director, Max India Ltd.
“This expansion enables us to provide our large pharmaceutical clients with our services to their regional affiliates in India and surrounding regions. For our biotech clients the expansion will provide them with access to patients and high quality research sites that will facilitate the completion of their clinical development programs. This is an important step for JSS Medical Research in its evolution as a niche global CRO and a major achievement for the Canadian and Quebec Health Care Research Industry because it is testimony to the fact that the quality and value of the scientific work done here transcends geographic borders and limits. I am indeed proud of this accomplishment and grateful to all of my staff and partners that have supported our company”, said Dr. John S. Sampalis CEO of JSS Medical Research.
Dr. Toni Rinow, CFO at JSS Medical Research added that JSS continues on its global expansion strategy and is seeking to further strengthen its position in the US and in Europe supported by its financial partners.
About JSS Medical Research
JSS Medical Research is a fullâservice Contract Research Organization with its corporate office in Montreal, Canada and a regional office in Bogota, Colombia. The company offers comprehensive clinical trial management services, from study design to publication of results, in Phase IâIV trials across a broad range of therapeutic areas. Biotechnology companies rely on the company’s knowledgeable project teams, and its customerâcentric and flexible approach to successfully conduct their critical early phase trials, while pharmaceutical companies can leverage its niche postâmarketing service offerings. With science and clinical epidemiological expertise at its core, JSS Medical Research is a leader in PostâApproval Clinical Epidemiology Studies (PACES) including PostâMarketing Observational Studies, Health Outcomes Research and Health Economics. Currently JSS Medical Research is conducting research studies in over 20 countries around the world for its clients which include the top 25 global Pharmaceutical companies and Biotechnology/Device companies, worldwide.
For more information, visit www.jssresearch.com
About Max Neeman International
Max Neeman International (MNI) is a full service CRO offering solutions for Phase II – IV clinical trials to pharmaceutical, biotechnology, generic and device companies. The company was founded in 2001 as a subsidiary of Max India Limited, a multiâbusiness corporate entity that is listed on the NSE and BSE. MNI has its headquarters in New Delhi with offices in six other cities in India and presence in AsiaâPacific, US and Europe. The company employs approximately 200 highly trained individuals the majority of which are physicians or other health care professionals. It provides full range of services including project management, data management, clinical trial supplies management, regulatory services and medical writing. These services are provided in a wide range of therapeutic areas including oncology, cardiology, neurosciences, infectious diseases, ophthalmology, dermatology and probiotics. The company has managed over 300 clinical trials for its clients. It has successfully passed 7 US FDA GCP audits and is ISO certified for project management, data management, Information Security Management System (ISMS) and Clinical Investigation of Medical Devices.
For more information, visit http://www.neemanâmedical.com